SAN FRANCISCO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Hagens Berman is investigating claims alleged in a new securities class action against Replimune Group, Inc. (NASDAQ: REPL) and its executives after the company's stock plummeted following the FDA’s rejection of its leading cancer drug, RP1. The lawsuit alleges that Replimune misled investors by overstating the drug’s trial data and failing to disclose critical regulatory risks. The filing, known as Jboor v. Replimune Group, Inc., et al., is on behalf of inve ...

Core Viewpoint - A securities class action lawsuit has been filed against Lockheed Martin Corporation, alleging misleading statements regarding the financial health of its Aeronautics and Rotary and Mission Systems (RMS) segments, impacting investors who purchased shares between January 23, 2024, and July 21, 2025 [1][2]. Allegations and Financial Fallout - The lawsuit claims Lockheed Martin failed to disclose ineffective internal controls and procedures for assessing program risks, leading to an overstatement of its ability to meet contractual commitments [2]. - The company reported significant pre-tax losses, including $1.8 billion in the Aeronautics segment on January 28, 2025, and an additional $950 million in pre-tax losses for the Aeronautics segment and $570 million for the RMS segment on July 22, 2025, attributed to issues with the Canadian Maritime Helicopter Program [6]. Investor Impact - Following negative disclosures, Lockheed Martin's stock price experienced a notable decline, with shares dropping almost 11% on the final disclosure [3]. - Hagens Berman is investigating these claims on behalf of investors who suffered substantial losses during the class period [4][5]. Company Management Changes - The resignation of the CFO was announced on April 17, 2025, which may indicate underlying issues within the company's management and financial reporting [6].

SAN FRANCISCO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- A class-action lawsuit is underway against Sable Offshore Corp. (NYSE: SOC), alleging the company and its executives misrepresented its oil production status to investors. The lawsuit, captioned Johnson v. Sable Offshore Corp., represents those who purchased or acquired the company's publicly traded securities between May 19, 2025, and June 3, 2025. It also includes investors who bought shares in the company's secondary public offering (SPO) on May 21, 2025. ...

SAN FRANCISCO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed on behalf of investors who purchased shares in KinderCare (NYSE: KLC) during its October 2024 initial public offering (IPO). The lawsuit alleges that the company made false and misleading statements in its IPO documents, failing to disclose significant risks related to the quality and safety of its childcare services. Hagens Berman urges KinderCare investors who suffered substantial losses to submit your losses ...

SAN FRANCISCO, Aug. 19, 2025 (GLOBE NEWSWIRE) -- On August 15, 2025, shares in Soleno Therapeutics, Inc. (NASDAQ: SLNO) experienced a significant drop following the release of a highly critical report by Scorpion Capital. Hagens Berman, a national shareholders rights firm, has opened an investigation into Soleno. The firm will investigate whether Soleno may have misled investors about VYKAT™ XR. The drug, a once-daily oral tablet, is designed to treat hyperphagia. Soleno has described this condition as "the ...

Core Viewpoint - A securities class action lawsuit has been filed against Lockheed Martin Corporation, alleging misleading statements regarding the company's financial performance and internal controls, particularly in its Aeronautics and Rotary and Mission Systems segments, leading to significant investor losses [1][2][6]. Group 1: Lawsuit Details - The lawsuit, Khan v. Lockheed Martin Corporation, seeks to represent investors who acquired Lockheed Martin securities between January 23, 2024, and July 21, 2025 [1]. - The lead plaintiff deadline for the lawsuit is set for September 26, 2025 [2]. - The lawsuit focuses on the accuracy of Lockheed Martin's statements regarding its Aeronautics and RMS business segments [2]. Group 2: Financial Performance Issues - Lockheed Martin reported $1.8 billion in pre-tax losses in its Aeronautics segment for the year ended December 31, 2024, citing "performance issues" [4]. - On July 22, 2025, the company announced an additional $950 million in pre-tax losses in the Aeronautics segment and $570 million in the RMS segment due to issues with the Canadian Maritime Helicopter Program [5]. - Following these announcements, Lockheed Martin's share price fell nearly 11% on July 22, 2025 [1]. Group 3: Allegations of Misleading Statements - The complaint alleges that Lockheed Martin made false and misleading statements while failing to disclose critical information about its financial health and operational risks [3][7]. - Specific allegations include a lack of effective internal controls regarding risk-adjusted contracts and an overstatement of the company's ability to meet contractual commitments [7]. - The investigation is focused on whether the company misled investors about the extent of its performance and financial problems [6].

Core Viewpoint - Telix Pharmaceuticals Limited is under investigation by the SEC, leading to a significant drop in the price of its American Depositary Shares after the announcement on July 23, 2025 [1][4]. Group 1: SEC Investigation - The SEC is investigating Telix regarding its disclosures related to the development of its prostate cancer therapeutic candidates [4]. - The investigation was triggered by Telix's announcement on July 22, 2025, which revealed the SEC's scrutiny [4]. Group 2: Shareholder Response - Hagens Berman, a national shareholders rights firm, has initiated an investigation to determine if Telix misled investors about its drug candidates [2][5]. - The firm is encouraging investors who have suffered substantial losses to come forward and submit their losses [2][5]. Group 3: Whistleblower Information - Individuals with non-public information about Telix are encouraged to assist in the investigation or consider the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery [7].

SAN FRANCISCO, July 29, 2025 (GLOBE NEWSWIRE) -- On July 23, 2025, investors in Telix Pharmaceuticals Limited (NASDAQ: TLX) saw the price of their American Depositary Shares significantly fall after the company revealed that it received a subpoena from the SEC. Telix’s revelation has prompted national shareholders rights firm Hagens Berman to open an investigation into whether Telix may have misled investors about certain of its drug candidates and urges Telix investors who suffered substantial losses to su ...

Core Viewpoint - Napco Security Technologies, Inc. is facing significant challenges, including a 21% decline in share price year-to-date, amid legal scrutiny and operational difficulties, particularly related to a securities class action lawsuit concerning its distribution practices and sales forecasting [1][2]. Financial Performance - Napco's third-quarter results for fiscal year 2025 showed a 10.8% year-over-year decrease in net sales, totaling $43.96 million, while earnings per share exceeded expectations at $0.36 compared to a forecast of $0.29. However, net income fell by over 23% year-over-year, attributed to inventory reductions by key distributors [2][4]. - The company reported a 25% drop in equipment sales in its February 3, 2025 earnings report, leading to a withdrawal of its 45% EBITDA margin target for fiscal 2026, which resulted in a 26% decline in share price in a single trading session [4][6]. Legal Issues - A class action lawsuit, Patel v. Napco Security Technologies, Inc., alleges that the company's leadership misled investors regarding its ability to forecast hardware demand and maintain margin targets, failing to disclose vulnerabilities in its distribution network [3][5]. - The lawsuit claims that optimistic statements about sales and margins were misleading, leading to inflated stock prices during the class period and substantial losses when the true financial situation was revealed [5][8]. Investigation - Hagens Berman, a shareholder rights firm, is investigating the allegations against Napco, focusing on whether the company misled investors about its sales forecasting and distribution practices [8][9].

Core Viewpoint - Iovance Biotherapeutics, Inc. is facing a securities class action lawsuit for allegedly misleading investors about its growth potential and ability to meet demand for its cancer treatments [1][2]. Group 1: Lawsuit Details - The lawsuit, Farberov v. Iovance Biotherapeutics, Inc., claims that the company made overwhelmingly positive statements while concealing material adverse facts regarding its operational readiness [2][5]. - The class period for the lawsuit is from May 9, 2024, to May 8, 2025, with a lead plaintiff deadline set for July 14, 2025 [2]. Group 2: Stock Performance - On May 9, 2025, Iovance's stock price dropped approximately 44.8%, falling from $3.17 to $1.75, following the announcement of disappointing financial results and a downward revision of revenue guidance [3]. Group 3: Financial Performance - In its July 2024 announcement, Iovance attributed the lower revenue guidance to a month-long reduction in manufacturing capacity due to maintenance, lower-than-expected sales of Proleukin, and a variable pace in the treatment of patients with newer therapies [4]. Group 4: Investor Claims - Investors argue that the disclosures revealed previously concealed issues that negatively impacted the company's growth prospects, contradicting earlier positive statements about its operational readiness [5].